CareDx, Inc
HealthcareNASDAQ:CDNA · NASDAQ Global Market
-$0.69 today
Vol 0.59M · Avg 0.71M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-7.0%
avg 44.3%
ROIC
-6.5%
avg -20.9%
ROA
-5.2%
avg -23.0%
Analysis
ROA is currently the strongest return metric at -5.2% versus its period average of -23.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John Walter Hanna Jr. | President, Chief Executive Officer & Director | $1.56M | — | 46 | $671,640.00 | 1.30% |
Keith S. Kennedy | CFO & COO | $1.06M | — | 56 | $221,548.00 | 0.43% |
Jessica Meng | Chief Commercial Officer | $849,327.00 | — | 51 | $169,392.00 | 0.33% |
Jeffrey A. Novack | General Counsel & Secretary | $590,794.00 | — | 42 | $112,632.00 | 0.22% |
Kashif Rathore | Chief Technology Officer | — | — | — | — | — |
Marica Grskovic | Chief Strategy Officer | — | — | — | — | — |
Jeffrey John Teuteberg | Chief Medical Officer | — | — | — | $112,632.00 | 0.22% |
Jennifer Foley | Chief Product Officer | — | — | — | — | — |
Natasha Moshirian Wagner | Vice President of Corporate Communications | — | — | — | — | — |
Jing Huang | Chief Data & Artificial Intelligence Officer | — | — | — | — | — |
Caroline Corner | Investor Relations | — | — | — | — | — |
Tina Jacobsen | Vice President of Investor Relations | — | — | — | — | — |
Robert N. Woodward | Chief Scientific Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$2.12M
Net Sentiment
$2.12M
Net selling
Most Active
Novack Jeffrey Adam
6 transactions
1–10 of 16
Analysis
Insiders reported 0 buys worth $0.00 and 16 sells worth $2.12M over the last 12 months. That adds up to net selling of $2.12M. Novack Jeffrey Adam was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +22.5% | +23.4% (12yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +22.5% over three years. Forward estimates point to Revenue at +23.4% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
Personalis, Inc.
NASDAQ:PSNL
$851.63M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
CorMedix Inc.
NASDAQ:CRMD
$685.67M
Castle Biosciences, Inc.
NASDAQ:CSTL
$627.83M
Evolent Health, Inc.
NYSE:EVH
$539.91M
Fulgent Genetics, Inc.
NASDAQ:FLGT
$530.52M
Myriad Genetics, Inc.
NASDAQ:MYGN
$408.96M
Embecta Corp.
NASDAQ:EMBC
$183.92M
DarioHealth Corp.
NASDAQ:DRIO
$51.63M
Who manages CDNA?
CareDx, Inc (CDNA) lists 13 active executives. The top listed executive is Jeffrey A. Novack, General Counsel & Secretary.
Are CDNA insiders buying or selling?
Recent insider activity shows net selling of $6.92M.
Explore More
Continue the stock analysis
Jump to another research area for this company.